stockrow
Friday 6 November 2026
Export ELVN’s income statement to Excel — free account
Enliven Therapeutics, Inc.
ELVN Healthcare Biotechnology
- EPS
- 0.00%
- Free cash flow
- −8.34%
Quarter to June 2026, against a year earlier
49.25
4.46
+9.96%
Follow ELVN
Alert me
Enliven Therapeutics, Inc. (ELVN) Book value per share
Enliven Therapeutics, Inc.'s book value per share at the end of fiscal 2025 was 8.1×, up 23.2% from 6.6× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 13.5×. Over the past ten years it has ranged from −6.1× (fiscal 2018) to 165× (fiscal 2019); the current reading is higher than 56% of that period. Enliven Therapeutics, Inc. ranks 59th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 8.1× | 23.22% |
| FY2024 | 6.6× | (4.85%) |
| FY2023 | 6.9× | (70.36%) |
| FY2022 | 23.3× | 46.93% |
| FY2021 | 15.9× | (34.50%) |
| FY2020 | 24.3× | (85.27%) |
| FY2019 | 165× | — |
| FY2018 | −6.1× | — |
| FY2017 | −0.9× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 13.5× | 87.38% |
| Mar 2026 | 7.2× | (10.99%) |
| Dec 2025 | 8.1× | 5.78% |
| Sep 2025 | 7.7× | (18.21%) |
| 26 more quarters | Free account |
Against its own ten years
Low −6.1×
High 165×
Ten-year median
8.1×
Current reading's percentile
56
Book value per share against peers
| Company | Book value per share |
|---|---|
| ELVN Enliven Therapeutics, Inc. | 13.5× |
| ACAD ACADIA Pharmaceuticals Inc. compare | 8.0× |
| VKTX Viking Therapeutics, Inc. compare | 5.0× |
| DNLI Denali Therapeutics Inc. compare | 4.9× |
| DYN Dyne Therapeutics, Inc. compare | 4.2× |
| TARS Tarsus Pharmaceuticals, Inc. compare | 2.2× |
| VRDN Viridian Therapeutics, Inc. compare | 0.0× |
| TLX Telix Pharmaceuticals Limited compare | 0.0× |
| CELC Celcuity, Inc. compare | −0.2× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))